Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

Fanying Meng(Shanghai University), Charles P. Hart(University of Auckland), Deepthi Bhupathi(University of Auckland), Qian Liu(Tianjin First Center Hospital), Yan Wang(Capital Medical University), Jessica D. Sun(Threshold Pharmaceuticals (United States)), Dharmendra Ahluwalia(Threshold Pharmaceuticals (United States)), Mark D. Matteucci(University of Auckland)
BMC Cancer
May 20, 2015
Cited by 24


Related Papers